A Phase 1/2 interventional study of CD5 CAR-T cells infusion in T-Cell Non-Hodgkin Lymphoma and T-cell Lymphoma (PTCL and CTCL), sponsored by Beijing GoBroad Hospital. Recruiting at 3 sites in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Beijing GoBroad Hospital · Phase 1/2, Interventional, and Treatment
Among 75 studies in Lymphoma, T-Cell with a site in China — 31 open to participants now, 34 under way, 4 of them phase 3. Lymphoma, T-Cell · China.
Among the 75 studies in Lymphoma, T-Cell with a site in China, this one is the 37th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 in phase 1/2, reaches primary completion later than 15 of the 33 other live ones, and was the 67th registered.
310 studies on the registry are indexed under Lymphoma, T-Cell; 78 are open to participants now.
Browse Lymphoma, T-Cell studies →31 of the 75 studies in Lymphoma, T-Cell with a site in China are open now. Recruiting first, the newest first:
Dizal Pharmaceuticals · Sites in China
Ruijin Hospital · Sites in China
Fudan University · Sites in China
The Affiliated Hospital of Xuzhou Medical University · Sites in China
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 68 Lymphoma, T-Cell studies recruiting now, 41 (60%) set no upper age limit and 21 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 14 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 37 · Phase 3 6 · Phase 4 3
First in 2007; this study’s year is marked. 10 started in 2025.
This study's planned enrollment of 36 is close to the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.
Median enrollment 38 across the 69 interventional studies, 525 across the 6 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 75 have an industry lead sponsor. The 10 most frequent:
Beijing GoBroad Hospital is the lead sponsor of 35 studies on the registry; 35 are open to participants now.
Beijing GoBroad Hospital has 2 studies filed under Lymphoma, T-Cell — fewer than ten, so there is no comparison to draw.
10 of the studies in Lymphoma, T-Cell with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06255795Phase 3Ruijin HospitalThe Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma | 2026-12-31 |
| NCT06716658Institute of Hematology & Blood Diseases Hospital, ChinaJAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | 2026-11-15 |
| NCT06733051Sun Yat-sen UniversityPhase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) | 2026-12 |
| NCT03952078Corvus Pharmaceuticals, Inc.A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | 2026-12-30 |
| NCT06314334Fudan UniversityScreening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma | 2026-12-30 |
Among the 75 studies in Lymphoma, T-Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
Inclusion Criteria (Patients who met all the inclusion criteria were eligible for enrolment):
Exclusion Criteria (Patients who fulfil any of the following criteria may not be enrolled):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled patients were treated with anti-CD5 CAR-T cells, with or without allo-HSCT bridging.
Drug: CD5 CAR-T cells infusion
Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
Dose-limiting toxicity (DLT)
Incidence and type of dose-limiting toxicity(DLT) within 21 days of CD5CAR-T infusion.
Time frame: 21 days
Adverse events (AEs)
Total number, incidence and severity of adverse events (AEs) within 21 days of CD5 CAR-T infusion.
Time frame: 21 days
Objective Response Rate (ORR)
The assessment of ORR by dose group at 21 and 90 Days after CD5 CAR T infusion.
Time frame: 21, 90 days
Duration of response (DOR)
DOR is defined as the date when CR response criteria are first met to the date of relapse or death caused by T-NHL in the absence of documented relapse
Time frame: up to 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.
Of 29 phase 1/2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 92. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing GoBroad Hospital